| Grab Sources And More Here: MYNZ Website. MYNZ Presentation. -----
And as I mentioned previously, (Nasdaq: MYNZ) has several potential catalysts of focus. Check them out:
#1. MYNZ Potential Catalyst - A Float This Small Could Create An Environment For Heightened Volatility.
According to info from the Yahoo Finance, MYNZ has a fairly low float.
The website reports this profile to have roughly 3.51Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with the volatility potential of this low float? -----
#2. MYNZ Potential Catalyst - A Maxim Group Analyst Tags MYNZ With A $14 Target.
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
Michael Okunewitch, an analyst at Maxim Group covering the biotechnology sector, has set a $14.00 target on Mainz Biomed as of 11/17/25 according to published info on the company’s website.
With this $14.00 target, there could be upside potential of over 900% for MYNZ from its closing valuation Tuesday. -----
#3. MYNZ Potential Catalyst - The Company Takes A Major Step Forward With Positive Topline Results.
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95%
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and utility of licensed proprietary biomarkers from Liquid Biosciences for developing an innovative screening test for pancreatic cancer. Researchers evaluated 18 licensed biomarkers across multiple candidate panels to streamline assay complexity. The leading panel achieved 100% sensitivity and 95% specificity, successfully distinguishing pancreatic cancer patients from healthy controls in a 30-subject cohort, reflecting different stages of the disease as well as precursors.
These findings are consistent with the strong performance previously demonstrated in discovery and validation datasets, which achieved 95% sensitivity and 98% specificity earlier this year. The reproducibility of these results further strengthens confidence in the robustness of the biomarker panel and its potential as the foundation of a reliable, non-invasive screening test.
Importantly, the algorithm developed by Liquid Biosciences not only distinguished pancreatic cancer from healthy controls but also successfully detected precancerous lesions that have the potential to develop into pancreatic cancer if left untreated. The ability to identify these lesions through a blood test opens the door to monitoring at-risk individuals, intervening earlier in the disease process, and ultimately reducing the incidence and mortality associated with pancreatic cancer.
“We are thrilled about the team’s progress in confirming the strong clinical results from our discovery study. What’s particularly exciting is that our algorithm and biomarker selection can identify neoplasms in blood. Delivering a blood-based test capable of detecting early stages of disease is a major step toward the early detection—and ultimately the elimination—of pancreatic cancer,” said Guido Baechler, CEO Mainz Biomed.
...
Read the full article here. -----
#4. MYNZ Potential Catalyst - The Company Knocks A Major Milestone Off Their List With A Commercial Launch In Switzerland.
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study
BERKELEY, Calif. and MAINZ, Germany, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert®, in Switzerland.
This milestone comes as the result of several key achievements. Earlier this year, Mainz Biomed signed a strategic partnership with labor team w ag (“labor team”), one of the country’s leading diagnostic laboratories. This collaboration provides a strong foundation for ColoAlert’s successful introduction, ensuring that patients and physicians across Switzerland will have access to the test through an established and trusted network.
Following this, Swissmedic, the Swiss authority responsible for therapeutic product regulation, granted official registration and marketing approval for ColoAlert®. This authorization enables the test to be distributed in Switzerland and marks an important regulatory step toward expanding patient access to innovative colorectal cancer screening solutions.
In addition, Mainz Biomed successfully completed a comprehensive technology transfer with labor team, enabling the laboratory to process and analyze ColoAlert® samples directly at its state-of-the-art facility in Goldach, Switzerland. This local implementation not only ensures operational efficiency but also guarantees that Swiss patients benefit from high-quality diagnostics performed within their own healthcare system.
Together, these accomplishments have paved the way for the commercial launch of ColoAlert®, making the test available to patients and healthcare providers throughout Switzerland.
...
Read the full article here. -----
#5. MYNZ Potential Catalyst - MYNZ To Showcase Key Solutions At MEDICA 2025 (One Of The World's Leading Heal-thcare Trade Shows).
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading heal-thcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany.
With over 5,000 exhibitors from 70 countries and 80,000 visitors expected, MEDICA continues to serve as a pioneering international platform for innovation, communication, and business development across the entire medical technology value chain. The event consistently sets trends for the future of global heal-thcare.
Bringing together heal-thcare experts, industry leaders, policymakers, and commercial decision-makers, MEDICA features an extensive program of high-level forums, conferences, and special exhibitions.
The event provides an excellent opp. to exchange insights, explore collaborations, and strengthen relationships with key opinion leaders shaping the future of cancer prevention and molecular diagnostics.
...
Read the full article here. -----
(Nasdaq: MYNZ) Recap - These 5 Potential Catalysts Put It On Our Radar
#1. A Float This Small Could Create An Environment For Heightened Volatility.
#2. A Maxim Group Analyst Tags MYNZ With A $14 Target.
#3. The Company Takes A Major Step Forward With Positive Topline Results.
#4. The Company Knocks A Major Milestone Off Their List With A Commercial Launch In Switzerland.
#5. MYNZ To Showcase Key Solutions At MEDICA 2025 (One Of The World's Leading Heal-thcare Trade Shows). -----
Coverage is now officially underway on Mainz Biomed N.V. (Nasdaq: MYNZ).
Be on the lookout for updates coming shortly. Talk soon.
Sincerely, Kai Parker StockWireNews
Sources: (1) Global Market Insights (2) https://www.who.int/news-room/fact-sheets/detail/cancer (3) Published by: Dollinger MM et al. Clin Lab 10/2018 (4) 98% overall satisfaction with ColoAlert® in our internal customer survey
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/17/2025 and ending on 11/18/2025 to publicly disseminate information about (MYNZ:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid one hundred ten thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and closely associated party owns shares in the Issuer, which you should assume the third party will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MYNZ:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/mynz-3lphe/#details | 
